Particularly, it is intriguing that lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor acetylhydrolase (PAF-AH) was identified as a potential factor in cerebrovascular oxidative stress and inflammation and risk factor for human dementia and subsequently drew considerable interest as a therapeutic target in Alzheimer’s disease (Davidson et al., 2012; Acharya et al., 2013; Fitzpatrick et al., 2014). This evidence concerns the gene PLA2G7 and Alzheimer disease.